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THEORETICAL REVIEW
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Abstract
Background: Treatment‐resistant depression (TRD) is a debilitating chronic mental
illness that confers increased morbidity and mortality, decreases the quality of life,
impairs occupational, social, and offspring development, and translates into increased costs on the healthcare system. The goal of this study is to reach an
agreement on the concept, definition, staging model, and assessment of TRD.
Methods: This study involved a review of the literature and a modified Delphi
process for consensus agreement. The Appraisal of Guidelines for Research &
Evaluation II guidelines were followed for the literature appraisal. Literature was
assessed for quality and strength of evidence using the grading, assessment,
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development, and evaluations system. Canadian national experts in depression were
invited for the modified Delphi process based on their prior clinical and research
expertize. Survey items were considered to have reached a consensus if 80% or
more of the experts supported the statement.
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Results: Fourteen Canadian experts were recruited for three rounds of surveys to

Amer M. Burhan, Ontario Shores Centre for
Mental Health Sciences, 700 Gordon St, Room
5‐3007, Whitby, ON L1N 5S9, Canada.
Email: burhana@ontarioshores.ca

reach a consensus on a total of 27 items. Experts agreed that a dimensional definition for treatment resistance was a useful concept to describe the heterogeneity
of this illness. The use of staging models and clinical scales was recommended in
evaluating depression. Risk factors and comorbidities were identified as potential
predictors for treatment resistance.
Conclusions: TRD is a meaningful concept both for clinical practice and research. An
operational definition for TRD will allow for opportunities to improve the validity of
predictors and therapeutic options for these patients.
KEYWORDS

Canada, comorbidity, consensus, depression, depressive disorder, major depressive disorder,
risk factors, treatment resistant
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would allow more personalized care to match patients with the right
treatment in a timely manner. Continued work on a more refined TRD

Depressive disorders constitute one of the most common disabling

definition and criteria can improve the comparability of research

diseases worldwide with an estimated prevalence of 264 million glob-

studies, enable international collaborations on the subject, and im-

ally (Disease, and Injury Incidence and Prevalence Collaborators, 2018).

prove treatment outcomes in major depressive disorder (MDD).

In the Canadian population, depression has a lifetime prevalence of
9.9% (Patten et al., 2015) with an estimated economic cost of 12 billion
dollars a year (Tanner et al., 2020). Among those who receive first‐line

2 |
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treatment for depression, approximately 50% do not achieve remission
and about two‐thirds require further sequential treatment trials to

This study involved two phases: (1) a literature review and (2) a

achieve remission (Ferrari et al., 2013; Rush, Trivedi, Wisniewski,

modified Delphi process to achieve expert consensus.

Stewart, et al., 2006). This disease burden confers increased morbidity

Phase 1 involved an evidence‐based literature review of TRD by

and mortality, decreases the quality of life (Alonso et al., 2011), impairs

a working group from Western University. This provided the

occupational, social, and offspring development (Greenberg et al., 2015;

groundwork for the development of initial questions and statements

Ishak et al., 2013; Lim et al., 2008), and translates into increased costs

for sharing with expert panel members. The Appraisal of Guidelines

on the health‐care system (Coiro et al., 2012; Weissman et al., 2014).

for Research & Evaluation II guidelines were followed throughout the

For both patients living with depression that does not remit despite

literature appraisal process (Hoffmann‐Esser et al., 2017). An ex-

multiple treatment trials, and clinicians providing treatment, consensus

perienced information specialist assisted in the development of the

on the definition, and treatment protocols for treatment‐resistant de-

literature search strategy. Initially, a literature search was conducted

pression (TRD) are needed.

for English‐language materials published between January 1, 1998

There is a lack of consensus on the definition of TRD. Broadly

and March 31, 2020 using MedLine, PsycINFO, and Cochrane

conceptualized as partial or no response to adequate evidence‐based

databases. Keywords included treatment‐resistant depression, re-

trials of treatment, TRD has a prevalence of up to 60% of the de-

fractory depression, difficult to treat depression, treatment, ther-

pression cohort (Berman et al., 1997). Treatment resistance may be

apeutics, risk factor, and diagnostic tools. Due to a large number of

conceptualized to include characteristics, such as chronic and persis-

publications, the search was subsequently limited to publications

tent symptoms of low mood, repeated depressive episodes, or poor

since January 1, 2013, as systematic reviews and meta‐analyses have

response to medications or other therapies. The challenges of defining

been synthesized regarding TRD before that date (Greden

TRD include the heterogeneity of the syndrome, lack of standardiza-

et al., 2011; Kasper & Montgomery, 2013).

tion of criteria for an “adequate trial,” and whether to include non-

Study selection of the most relevant sources was conducted

pharmacological treatments, resulting in a lack of consensus and

separately by two reviewers to reduce the possibility of omission of

validity of definition. The most utilized definition in the last 2 decades

relevant publications (Yuri E. Rybak and Ka S. P. Lai). This review was

with support from the largest naturalistic trial (sequenced treatment

focused and selective rather than a systematic review, and the au-

alternatives to relieve depression [STAR*D]) is the lack of response

thors decided to include or exclude papers based on the pertinence

after two antidepressant treatment trials (Berman et al., 1997).

of the information it contained. Literature was combined based on

Several countries have suggested an internationally accepted TRD

themes relevant to treatment resistance including definition, risk

definition (Vaccarino & Kennedy, 2020), but unanimity has been

factors, and diagnostic tools (Supporting Information 1). These re-

elusive (Fava, 2003).

viewers then independently assessed each study for the quality and

Having a consensus for the definition of TRD could improve and

strength of evidence using the grading, assessment, development,

standardize care by indicating when a treatment resistance algo-

and evaluation (GRADE) system (Guyatt et al., 2011). The GRADE

rithm should start. No current definition provides sufficient detail for

system provides a systematic approach to review literature based on

the accurate triaging and staging of patients in clinical settings or

a guideline developed by researchers worldwide. The GRADE system

proper assessment for the selection of research participants.

rates evidence based on five criteria: risk of bias; publication bias;

Therefore, since the late 1990s, researchers have proposed more

imprecision; inconsistency; and indirectness. Each criterion can be

detailed staging models intended to serve both clinical and research

rated as having an unlikely risk of bias to a high risk of bias. The

needs. The lack of a universally accepted staging model or a con-

process of quality of evidence assessment and risk of bias is provided

sensus definition for TRD creates ongoing barriers for patients to

in Supporting Information 2. On the basis of five criteria, an overall

receive the appropriate care based on the severity, chronicity, and

rating for the quality of evidence was assigned.

treatment response.

GRADE suggests that randomized controlled trials start as high‐

The goal of this study is to reach an agreement on the concept,

quality evidence and observational studies as low‐quality evidence,

definition, staging model, and assessment of TRD. Creating an optimal

and in accordance with the GRADE criteria, each article is rated as

definition for TRD will help improve research to address patient

providing a weak, moderate, or high certainty of evidence

needs, better define this heterogeneous population, and allow clin-

(Table 1) (Burns et al., 2011; Schünemann et al., 2013). The GRADE

icians to communicate using the same terminology. Operationally, this

system is a widely accepted tool used in the process of building

|
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T A B L E 1 Level and grades of evidence based on the grading, assessment, development, and evaluation system (Burns et al., 2011;
Schünemann et al., 2013)
Grade

Definition

High

We are very confident that the true effect is close to that of the estimate of the effect

Moderate

We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different

Low

Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect

Very Low

We have very little confidence in the effect estimate: The true effect is likely to be substantially different from
the estimate of effect

recommendations

and

answering

clinical

questions

with

3 |
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recommendations. A third reviewer (Amer M. Burhan) resolved
disagreements in ratings between the two reviewers to assist in

Results are presented as a logical sequence of essential questions

reaching a consensus.

and answers to assist with clinical and research utility. Each

Once the Phase 1 literature review was completed, the recruit-

item contains a body of evidence‐based literature review and

ment of experts for Phase 2 began. Experts were approached via

the experts’ consensus opinions. The consensus results are

recruitment emails. Experts were selected based on the following

complemented by the experts’ comments. Table 2 presents the

criteria: currently, a consultant psychiatrist in a Canadian academic

summary of the 27 items which reached consensus from this group

center as an expert in mood disorders, currently an academic expert

of experts.

contributing in the field of mood disorders, and agreement to participate in the Delphi method. To be considered as an academic expert,
the individual must have met at least one of the following criteria:

3.1 | Is TRD a useful concept?

involvement in one or more international TRD organizations, authorship on one or more articles in mood disorders in a peer‐reviewed

The concept of TRD captures clinical reality since it reflects a large

journal during the preceding 2 years, or involved in responsibilities

clinical population with a common clinical outcome. It is not a new

related to the provision of teaching in mood disorders for over 1 year.

concept as the term has been utilized by the mental health com-

Overall, 18 national experts from seven Canadian universities

munity since the 1970s. Historically, it has survived over more than 4

(University of British Columbia, University of Calgary, McGill

decades and has periodically attracted more attention every time a

University, University of Ottawa, Queen's University, University of

new potentially effective treatment emerges.

Toronto, and Western University) were selected. Of the 18 experts

As with any concept, however, TRD does not perfectly fit

contacted, 14 agreed to participate in the consensus‐building pro-

the clinical variability of real‐life cases. Each of the two major

cess. Two initial meetings were held to discuss the need for a defi-

components of the concept, response and treatment, has inherent

nition of TRD, the current gaps in the literature, and the consensus

limitations when it comes to individual responses. For instance, the

process. We used the modified Delphi methodology to generate

line between response and nonresponse is clouded by partial

consensus via an iterative process until the agreement was reached

responders, fully refractory cases and those with very different

(Figure 1). In contrast to the traditional Delphi methodology, a

sets of symptoms and heterogeneity of treatment resistance

modified Delphi methodology was adopted allowing for the creation

(Malhi & Byrow, 2016). The treatment component is often char-

of initial questions and statements based on current knowledge and

acterized as treatment adequacy and may be difficult to assess due

literature. This facilitated the more efficient development of sub-

to the variability of treatment options, the match between treat-

sequent statements and recommendations.

ment and sets of symptoms, or the presence of comorbid condi-

Experts communicated their findings via Survey Monkey

tions and psychosocial factors.

(https://surveymonkey.com/). Please see Supporting Information

Despite the imprecision of the concept of TRD, the expert panel

3 for full surveys distributed. Items were considered to have reached

reiterated its usefulness both for clinical practice and research. In the

a consensus if 80% or more of the experts rated the item as “agree”

first round of the survey, 92% felt that TRD is a meaningful concept

or “strongly agree.” Statements that reached consensus in one round

and 85% of respondents use a TRD definition in their clinical prac-

were not represented in the subsequent round. Where survey items

tice. All (100%) respondents indicated that an operational definition

achieved less than 80% of the agreement as “agree” or “strongly

of TRD was needed. A definition for TRD helps clinicians to become

agree,” these items were either rephrased for the next round or

aware of the persistence of depression in individual cases in a timely

omitted depending on the comments from the experts. Data were

fashion and to foresee potential treatment challenges and consider

ultimately synthesized for narrative review.

more effective interventions.
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F I G U R E 1 Modified Delphi methodology. Three rounds of surveys were conducted to reach a consensus on a total of 27 items. Items that
were reformulated may have been summarized into a single item or reworded as multiple items for improved clarity. *Grip strength,
neuroticism, personality traits, social inhibition, body mass index, age, height, and biomarkers questions were excluded given low approval
ratings by experts and lack of current literature support. HAM‐D‐24 was excluded given preference for the HAM‐D‐17. #Items #2–4
(melancholic features, atypical features, number of stressful life events), #6–14 (various depression and comorbidity scales), #18 (having both
dichotomous and dimensional definitions), and #22 (definition to include psychotherapy) were excluded given low approval ratings by
experts. &Items #2 and #3 (recommendation of a clinical staging tool) were excluded given low approval ratings by experts. HAM‐D, Hamilton
depression rating scale

3.2 | A dichotomous versus dimensional approach
to TRD?

clinical reality, as was shown in antidepressant treatment switch
trials including STAR*D. (Rush, Kraemer, et al., 2006; Rush, Trivedi,
Wisniewski, Stewart, et al., 2006) Nevertheless, the dichotomous

Although TRD has been historically defined as a dichotomy (i.e., ca-

definition aids in identifying and differentiating responders from

tegorically), this definition has been criticized as not representing

those with less severe forms of treatment resistance. In this capacity,

460
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T A B L E 2 Summary of statements from the modified Delphi
methodology
Statement

Level of
Agreement

ET AL.

it has been used in research and practice guidelines for several
decades (Malhi & Byrow, 2016; Murphy et al., 2017; Pérez‐Wehbe
et al., 2014). Panelists’ indicated that the dichotomous definition may
be more suited to an initial stage of TRD. Experts favored using only
the dimensional concept to delineate the progression or severity of

Treatment‐resistant depression (TRD) as a categorical
or dimensional definition

TRD (92%).

A definition for TRD is currently being used in
clinical practice by the expert.

85%

TRD is a meaningful concept in clinical practice.

92%

refined transitional diagnostic approach with the potential to improve

An operational definition for TRD is needed for
clinicians and researchers.

100%

the logic and timing of intervention (McGorry & Hickie, 2019). The

TRD should be defined in a dimensional sense only

92%

The continuous approach (referred to from here on as dimensional) utilizes a staging model as a tool. It was proposed as a more

Definition of the initial stage of TRD

opinion was that with advancing treatment resistance, it becomes
increasingly obvious that treatment is not a one‐size‐fits‐all concept.
On the basis of unanimous expert opinion, TRD staging models have

TRD should be defined by the failure of two
adequately dosed and evidence supported trials
of antidepressant medications.

83%

Nonresponse in TRD should be defined as less than
50% reduction in symptom severity

83%

The minimum length of the antidepressant trial
should be 4–6 weeks

83%

concept to evaluate the stages of progression in TRD.

83%

3.3 | What is the operational definition for initial
treatment resistance?

Anxiety comorbidity

93%

On the basis of the most recent systematic review, no agreed‐upon

Psychotic features

93%

dichotomous definition exists for TRD (GRADE‐high) (Gaynes

A higher number of lifetime depressive episodes

100%

et al., 2018). Although experts often agree on a requirement for

Partial remission

92%

two treatment failures, they do not agree on the definition for the

Number of lifetime episodes

93%

adequacy of either dose or duration or outcome measures. Defini-

Number of previous antidepressant trials

92%

tions do not regularly incorporate failure with regard to augmenta-

Number of previous augmentation agents

86%

tion agents (Vaccarino & Kennedy, 2020). Besides differences in

Previously failed psychotherapy

100%

criteria, none of the definitions of TRD have been systematically

Previous failed ECT

93%

examined for reliability and predictive value utility (GRADE‐high;

The long duration of illness

85%

Gaynes et al., 2018; Souery et al., 2006). In reviewing the STAR*D

Symptom severity of the current episode

100%

reports, one can clearly see that the crucial point at which the risk of

Greater number of hospitalizations

92%

Prevalence of comorbidities (psychiatric and
medical)

92%

Comorbid personality disorder

92%

relevance in both clinical practice and research. A scoring system can
define clarify heterogeneity within the very diverse TRD population.
The experts accommodated both concepts favoring the dichotomy
concept to define initial treatment resistance and the dimensional

Evaluation
HAM‐D‐17 should be used in the ongoing
assessment of depressive symptoms
Risk factors and comorbidities

Comorbid medical illness

86%

Comorbid substance use

100%

Bipolarity features

92%

Current psychosocial stressors

93%

failures (Rush, Trivedi, Wisniewski, Nierenberg, et al., 2006).
Recent reviews usually define failure to respond as “lack of decrease in depressive severity of at least 50%” (GRADE‐high) (Gaynes
et al., 2018). The report from the European Group for the Study of
Resistant Depression identifies resistance as less than 50% symptom
reduction (Bartova et al., 2019). Although reports do not consistently
agree on a definition of adequate dose and duration, the minimum

Assessment/staging models
TRD staging models have clinical relevance in both
clinical practice and research

treatment resistance markedly increased was after two treatment

93%

The DM‐TRD is recommended as a clinical staging
tool in TRD

72%

The Maudsley staging model is recommended as a
clinical staging tool in TRD

45%

duration cited is typically 4 weeks (Gaynes et al., 2018), and the
range of 4–12 weeks (Ng et al., 2019). This expert panel proposes the
following criteria for initial treatment resistance (Table 3).
The treatment failure component of the definition of TRD revealed a diversity of opinions among experts based on conflicting
data on the effectiveness of switching antidepressants and the

Note: Statements were considered to have reached consensus if 80% or
more of the experts rated the item as “agree” or “strongly agree.”

benefits of using antidepressants from different groups in managing

Abbreviations: DM‐TRD, Dutch measure for quantification of treatment
resistance in depression; ECT, electroconvulsive therapy; HAM‐D‐17,
Hamilton depression rating scale (17‐items).

scribing medications from the same class or different classes and

TRD. There exists mixed evidence regarding the advantages of pretherefore this study deliberately did not explore this (Bschor
et al., 2018; Carvalho et al., 2014). The other area of consideration is
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Operational definition suggested for the initial stage of treatment‐resistant depression (TRD)

Operational criteria

Quality of evidence

Level of agreement

TRD should be defined by the failure to achieve response to two adequately dosed and evidence
supported trials of antidepressant medications

GRADE‐high

83%, 10/12

Nonresponse should be defined as less than 50% symptom reduction

GRADE‐high

83%, 10/12

The minimal length of antidepressants trial should be defined as 4–6 weeks

GRADE‐high

83%, 10/12

Abbreviation: GRADE, grading, assessment, development, and evaluation.

how the failure of an antidepressant trial is defined. On one hand,

evidence‐based psychotherapy.” However, failure to respond to psy-

failure of two antidepressants can mean nonresponse during the

chotherapy was strongly recommended as a risk factor and indicator

initiation of treatment, but the failure of an antidepressant may also

for the severity of treatment resistance (100%). The importance of

occur during the maintenance phase of treatment with the relapse of

psychotherapy at the early stage of depression was not disputed, but

a depressive episode following a remission despite being on ade-

psychotherapy failure was not included mainly for practicality and

quate doses of medication. The mechanism of tachyphylaxis remains

feasibility. One of the main reasons outlined by the experts was dif-

unclear and continues to be under investigation (Targum, 2014).

ficulty standardizing this form of treatment. Although the standard

Given the multifactorial etiology for medication failures, these con-

has been well developed in research trials, in practice many factors,

siderations further warrant a dimensional approach to define TRD

such as therapist training, expertize, therapeutic rapport, and patients’

and clarify the heterogeneity of this population.

readiness for change may be difficult to capture. The other barrier is
accessibility as psychotherapy is not always available. Overall, this
study emphasizes the importance of the role of psychotherapy in the

3.4 | Should other treatments such as
psychotherapy be included in the initial definition
of TRD?
Historically, definitions of TRD do not incorporate psychotherapy.

comprehensive assessment of treatment resistance.

3.5 | How should an evaluation of advanced
resistance and dimensional definition be conducted?

Even though there is robust evidence for treatments such as
cognitive‐behavioral therapy and interpersonal therapy in mild‐to‐

The principle of clinical staging for depression was first proposed by

moderate depression, definitions of TRD have primarily a pharma-

Sackeim et al. (1990) who introduced the antidepressant treatment

cological basis and (Cuijpers et al., 2016; Parikh et al., 2016; Ruhe

history form which was further developed by Sackeim et al. (1990) and

et al., 2012) this omission is repeatedly highlighted as sig-

Thase and Rush (1997). Since initial development, a number of scales

nificant (Conway et al., 2017; Gronemann et al., 2018).

have been developed including the Antidepressant Treatment Response

Evidence‐based psychological treatments are widely accepted as

Questionnaire, a user‐friendly tool for assessment of prior anti-

essential components of initial treatment for depression in most

depressant trials (Chandler et al., 2010; Desseilles et al., 2011). More

reputable national guidelines, such as the Canadian Mood and

recent staging models such as the Maudsley staging model (MSM) and

Anxiety Treatment (Lam et al., 2016), National Institute for Health

the Dutch measure for quantification of treatment resistance in de-

and Care Excellence (National Collaborating Centre for Mental

pression (DM‐TRD) are among the most evidence‐based and compre-

Health, 2010), American Psychological Association (Gelenberg

hensive in 2020. Both staging models are promising clinician‐rated

et al., 2010), and the Royal Australian and New Zealand College of

prediction tools for the expected course of depression in a broad po-

Psychiatrists (Malhi et al., 2015). In the most recently published

pulation of patients (GRADE‐moderate) (van Belkum et al., 2018;

Health Quality Ontario Standards, after initial diagnosis is made,

Fekadu et al., 2009).

treatment requires the following: people with major depression have

There are many practical benefits to using staging models as it

timely access to either antidepressant medication or evidence‐based

leads to more refined, personalized, and extended diagnoses to

psychotherapy based on their preference (Health Quality Ontario,

outline an accurate treatment plan (Ruhe et al., 2012). Once com-

2018). People with severe or persistent depression should be

pleted, a staging model serves as a concise source of valuable long-

offered a combination of both treatments. Failure to respond to

itudinal information that assists busy clinicians to make better‐

psychotherapy has been included in TRD definitions in the past

informed choices of the next treatment option. Thus, the inclusion of

(Wijeratne & Sachdev, 2008) and one of the more recent proposed

staging models has the potential to improve communication among

definitions of TRD (Conway et al., 2017).

physicians during the referral process and help match the correct

Despite this, only 54% of experts supported the statement “TRD

treatment for the patient, whether it be antidepressant medication,

should be defined by failure of two adequately dosed and evidence

augmentation, psychotherapy, ketamine, therapeutic brain stimula-

supported trials of antidepressant medications and one course of

tion, or other treatments.
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In the second round of the Delphi process, 93% of the expert

with multiple subtypes together (e.g., have both melancholic and

panelists feel that TRD staging models have relevance in both clinical

atypical features), and patients may not rate as severely depressed

practice and research. The DM‐TRD is more comprehensive and in-

using objective scales such as the Hamilton depression rating scale.

cludes ratings for functional impairment, psychosocial stressors, and

Convincing evidence emerged on the following group of factors

comorbidities. The DM‐TRD has been found to outperform the MSM in

reflecting the severity of current depressive symptoms. Higher

its ability to predict future depressive symptomatology (GRADE‐high;

baseline symptom severity is one of the strongest predictors of poor

van Dijk et al., 2019; Peeters et al., 2016). On the basis of a naturalistic

response (Gronemann et al., 2018; Nuñez et al., 2018; Peeters

study, the DM‐TRD has also predicted the Beck depression inventory

et al., 2016) and lower remission rates (GRADE‐high; Bartova

(BDI) scores, the severity of future depressive symptoms, and the de-

et al., 2019; De Carlo et al., 2016). The longer duration of the

gree of remission at week 16 (GRADE‐high) (Peeters et al., 2016).

current episode has also been found to increase the risk of TRD

Both staging models were supported by the panel with pre-

(GRADE‐moderate; Kautzky et al., 2019). The expert panel reached

ference given to DM‐TRD (75%) over MSM (50%). Apart from higher

consensus with at least 85% on all of the above factors: Higher

predictive capacity, the inclusion of psychotherapy trial failure was

baseline severity, lower remission rates, and longer duration of the

another advantage of the DM‐TRD that the panel valued. This was a

current episode.

logical step, given unanimous approval of previously failed psy-

When there is clinical suspicion for bipolarity in unipolar de-

chotherapy trials as an important risk factor for TRD. Furthermore,

pression, literature has suggested the possibility of a more severe

the inclusion of functional disability and comorbidities are additional

course of illness with higher symptom severity, suicidality, and poor

benefits for a comprehensive evaluation. The expert panelists ex-

response to antidepressants

(Rybakowski, 2012; Serretti

&

pressed concerns that the DM‐TRD takes more time to complete,

Fabbri, 2013; Souery et al., 2012). There is evidence that patients

although when completed during history taking or for a familiar

with TRD have high rates of undiagnosed or hidden bipolar dis-

patient, it may take only 5 min. Thus, the use of an objective staging

order (Correa et al., 2010). Therefore, clinicians are encouraged to be

tool is recommended to rating the severity and extent of treatment

vigilant in screening for bipolarity using validated rating scales and to

resistance.

obtain a collateral history from informants. Features of bipolarity
(e.g., family history of bipolar disorder) as a risk factor received approval by the panel at 92% level.

3.6 | What clinical risk factors predispose an
individual to TRD?

Evidence has been found for the group of factors reflecting the
course of depression. A higher number of lifetime depressive episodes was replicated as one of the most prominent risk factors for

Evidence about what risk factors are associated with a TRD diagnosis

TRD (GRADE‐moderate; Kautzky et al., 2019; Souery et al., 2006). A

is remarkably limited (GRADE‐high) (Bennabi et al., 2015; Gaynes

greater number of prior antidepressant trials also increased the risk

et al., 2018). Clinical factors have been found to predict increasing

of TRD (GRADE‐moderate; Kautzky et al., 2019). A greater number

odds of developing TRD including comorbidities such as generalized

of hospitalizations was associated with a lower response rate (De

anxiety disorder, panic disorder, and psychosis (GRADE‐moderate;

Carlo et al., 2016). Even if the patient had more than one hospitali-

Kautzky et al., 2019). Comorbid anxiety disorders have been

zation, there were associations with poorer outcomes and non-

replicated as one of the most prominent risk factors for TRD

response to at least two antidepressants (Souery et al., 2006). These

(GRADE‐moderate; Cepeda et al., 2018; Kautzky et al., 2019; Souery

factors are consistent with other clinical factors such as the longer

et al., 2006) and associations for a poorer response, although no

duration of a current depressive episode. In addition, the number of

clear association on remission rates (GRADE‐moderate; De Carlo

previous augmentation trials as well as electroconvulsive therapy

et al., 2016). Consistent with the literature, this panel almost unan-

(ECT) failure is recommended to be included in the assessment of

imously agreed with the increased risk of TRD in the presence of

more advanced stages of resistance. However, clinicians must be

both anxiety (93%) and psychotic features (93%) (Table 4).

mindful that it is possible for a patient to be falsely considered

Inconsistent evidence has been found for subtypes of major

“treatment resistant” to ECT as there may have been the poor

depression (GRADE‐moderate; De Carlo et al., 2016; Gronemann

quality of ECT or inadequate electrical charge in relation to a

et al., 2018). Melancholic features have been found in the literature

climbing seizure threshold. Failure of evidence‐based psychotherapy

to increase the likelihood of both nonresponse and non‐remission

trials as a risk factor was unanimously approved by the panel. The

(GRADE‐moderate; De Carlo et al., 2016; Souery et al., 2006). Expert

expert panel reached a consensus with at least 85% approval on all

panelists have commented that subtypes should remain as part of an

of the above factors.

assessment for TRD as melancholic features may predict TRD and

Comorbid personality disorders have also been associated with

atypical features may suggest bipolarity. However, the expert pa-

decreased response rates in some studies (Fava et al., 1996;

nelists did not reach a consensus in finding certain subtypes of de-

Takahashi et al., 2013) and decreased remission rates (GRADE‐

pression to be risk factors in the development of TRD (50% for

moderate). Substance abuse has been associated with a poorer re-

melancholic and 42% for atypical features). Experts have suggested

sponse to antidepressant treatment (Bennabi et al., 2015; van Dijk

that despite the evidence, patients with these subtypes may present

et al., 2019). As personality and substance use disorders may often
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Clinical risk factor

Quality of evidence

Level of agreement

Symptom severity of the current episode

GRADE‐high

100%, 14/14

Frequent and recurrent depressive episode

GRADE‐high

100%, 14/14

The long duration of illness

GRADE‐moderate

85%, 11/13

Current psychosocial stressors

GRADE‐moderate

93%, 13/14

Number of lifetime episodes

GRADE‐moderate

93%, 13/14

Bipolarity features (e.g., family history)

GRADE‐moderate

92%, 12/13

Current psychosocial stressors

GRADE‐moderate

93%, 13/14

Stressful life events or trauma

GRADE‐moderate

85%, 11/13

Comorbidity

Level of evidence

Level of agreement

Anxiety

GRADE‐moderate

93%, 13/14

Psychotic features

GRADE‐moderate

93%, 13/14

Personality disorders

GRADE‐moderate

92%, 12/13

Substance use disorders

GRADE‐moderate

100%, 14/14

Comorbid medical illness

GRADE‐moderate

86%, 12/14

Level of evidence

Level of agreement

Treatment factors
Number of previous antidepressant trials

GRADE‐moderate

92%, 12/13

Number of previous augmentation agents

GRADE‐moderate

86%, 12/14

Failed psychotherapy trials

GRADE‐moderate

100%, 11/11

Previously failed trial of electroconvulsive
therapy

GRADE‐moderate

93%, 13/14

Greater number of hospitalizations

GRADE‐moderate

92%, 12/13
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T A B L E 4 Risk factors for the
development of treatment‐resistant
depression

Note: Considerations include clinical risk factors, comorbidities, and treatment risk factors.
Abbreviation: GRADE, grading, assessment, development, and evaluation.

masquerade as depression, a careful longitudinal history is important
to establish accurate psychiatric diagnoses. The expert panel re-

3.7 | Are there any evidence‐based clinical scales
for the assessment of depressive symptoms in TRD?

commended that personality and substance use disorders should be
strongly considered as risk factors (consensus was above 90%).

Clinical scales have been recommended to objectively track treat-

Unexpectedly, medical comorbidities as a risk factor showed no

ment response. The most commonly used measures of symptom

clear evidence that it is associated with decreased response rates

severity for depression are the Hamilton depression rating scale

either (De Carlo et al., 2016; Fava et al., 1996). Nevertheless, medical

(HAM‐D) (Hamilton, 1960) and Montgomery–Asberg depression

comorbidities may play a significant role in poor recovery and cer-

rating scale (MADRS) (Montgomery & Asberg, 1979), and the pre-

tainly should be considered individually (Bennabi et al., 2015). Thus,

ferred outcome measures in TRD are the HAM‐D and clinical global

it was endorsed by the panel as a significant risk factor (86%).

impressions (GRADE‐high; Gaynes et al., 2018). Overall, the HAM‐D

Often omitted in TRD literature, stressful life events and trau-

is the most frequently used tool by research, with the HAM‐D‐17 the

matic experiences are now gaining more attention. Childhood ad-

most commonly applied. Regardless of the instrument used, the

versity has recently been claimed the single biggest contributor to

preferred outcome measure in studies is remission of depressive

psychiatric disorders (Lippard & Nemeroff, 2020), but evidence of its

symptoms using a standardized and validated instrument.

role in TRD is notably still lacking. In one of the most recent studies,

Among this group of experts, as a clinician‐rated tool, the HAM‐

the inclusion of childhood adversity as a factor did not improve a

D‐17 is recommended as a scale for ongoing assessment of TRD

model's predictive value (van Dijk et al., 2019). The statement was

(91%). Experts find that the HAM‐D‐17 is reliable for comparisons

formulated for the experts using a general term as “stressful life

with previous studies and most practical. As a self‐report scale, the

events or trauma” which received strong support among the experts

patient health questionnaire‐9 is simple and easy to administer in

as a risk factor for the development of TRD (85%). Current stressful

clinical practice, although maybe best used as a screening

life events as a risk factor for the development of TRD was also

tool (Kroenke et al., 2001). Other scales such as the MADRS or

approved by 93% of the panel. Notably, these two and medical co-

BDI‐II may not be as familiar to clinicians (Beck et al., 1996). It was

morbidities are the only risk factors that we have decided to include

agreed that regardless of the scale used, it is important to have a

in the consensus process despite conflicting research evidence.

measure of symptom severity.
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3.8 | Are there any evidence‐based clinical scales
for the assessment of psychiatric comorbidities in the
setting of TRD?
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available, these treatment modalities can be considered as part of
the staging and prognostication of TRD. For example, at the time of
this study, access to repetitive transcranial magnetic stimulation
(rTMS) is currently restricted in Canada, as only 3 (Alberta, Quebec,

Few researchers have investigated scales to specifically assess

and Saskatchewan) out of 10 provinces have publicly funded rTMS

psychiatric comorbidities in individuals with MDD. As such, there is

availability.

no consensus regarding which screening instruments to use in the

Future empirical studies should address the inconsistencies be-

setting of TRD to assess for comorbidities, but rather to rely on

tween current evidence‐ and expert‐based guidelines in TRD. For

clinical judgment. As with any screening instrument, concerns are

example, the current literature suggests that a history of trauma may

related to the length of the instrument and thus practicality. Overall,

not necessarily be predictive of TRD, although empirically one can

the literature suggests that the Mini International Neuropsychiatric

hypothesize that severe trauma could predispose a patient to

Interview remains a thorough tool to review diagnostic considera-

treatment resistance. Therefore, studies may wish to study the role

tions in depression such as bipolar disorder, anxiety disorders, and

of patient resiliency as a protective factor or explore how trauma‐

posttraumatic stress disorder while being shorter and less tedious

informed interventions may help patients process these life

than the structured clinical interview for the DSM (First et al., 1997;

experiences.

Sheehan et al., 1998). However, only 58% of the experts endorsed
using this tool in the initial assessment of TRD.

As novel treatment modalities are studied for TRD, this group of
experts agreed that ongoing objective clinical scales should be used

One can look to specific disorders to find a screening tool that

in tracking symptoms of depression and their comorbidities. With

best fits that diagnosis. At this time, there are no specific assessment

advances in mobile health technologies and applications, patient self‐

tools that are specifically recommended by this group of experts to

reported outcome scales may be useful in tracking symptom change

be used in TRD. However, as with any disorder, the use of an ob-

in real‐time to offer valuable information about the effectiveness of

jective instrument can be valuable as a measure of symptom severity

treatment strategies. It is hoped that having an operational definition

if that specific comorbid diagnosis is present. Thus, we would re-

for TRD will allow researchers to use common clinical terminology

commend using an objective instrument to track symptom severity

and allow for new treatments to be studied in the future for these

of comorbid psychiatric disorders in the setting of TRD.

patients.

Of note, rephrasing the statement for endorsement was done
between Rounds 2 and 3. Experts were more amenable to the en-
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